

POSTER LISTING

PRESENTER	TITLE OF PRESENTATION	#
FARSANA AHMAD	Engaging and Curing Active Drug Users of Hepatitis C	01
OLGA ANAGNOSTOU	Recent Syringe Sharing, Long Injecting History, Past Incarceration and Not Living with the Family are Independently Associated with Hepatitis C Virus (HCV) Infection among People who Inject Drugs (PWID) in Greece	02
AMBER ARAIN	Pilot Study: Combining Formal and Peer Education with Fibroscan to Increase HCV Screening and Treatment in Persons Who Inject Drugs	03
AMBER ARAIN	Uptake for HCV Screening and Treatment in Persons in Opiate Substitution Therapy (POST) in Belgium	04
ELISABETH AVRIL	From Awareness to Treatment: A Comprehensive HCV Model of Care	05
ELISABETH AVRIL	The Mobile Hepatitis Screening Program: An Innovative Project among People who Use Drugs in Paris Region	06
DAVID BAKER	Treating Hepatitis C, HIV and Opiate Dependency in a Sydney General Practice: Opportunities and Challenges	07
DAVID BAKER	Fibroscan Screening to Detect Advance Liver Disease in People Living with Hepatitis C Attending an Australian General Practice: A Pilot Program	08
STEFAN BOURGEOIS	The Modelled Impact of Improved Hepatitis C Virus (HCV) Treatment Strategies on HCV Prevalence among People who Inject Drugs (PWIDS) in Belgium	09
PHILIP BRUGGMANN	Access to Hepatitis C Care for Underserved PWID: Provision Rapid Testing and Fibrosis Assessment in Drug Consumption Rooms	10
PHILIP BRUGGMANN	Hepatitis C Virus Prevalence among People who Inject Drugs in Switzerland	11
TONY BUTLER	Willingness to be Treated for Hepatitis C among Prisoners: Results from the National Prison Entrants' Bloodborne Virus and Risk Behaviour Survey (NPBBVS)	12
KERRY BUTLER	Hepatitis C and Associated Injecting Risk Behaviours in People Who Inject Drugs	13
ERIKA CASTRO	Standard of Care of Hepatitis C in the Addiction Medicine Clinic Centre St-Martin	14
ERIKA CASTRO	Swiss Data on Hepatitis C Treatment in People who use Drugs: The SAMMSU Cohort	15
CRAIG CONNELLY	Hepatitis C Treatment Access Via a Community Drug Treatment Service	16
MARIE DEBRUS	Positive Impact of a Community-Based Educational Intervention on Access to HCV Testing in Difficult-To-Reach People who Inject Drugs: Results from the ANRS-AERLI Study	17
JOHN DILLON	Preferences for Hepatitis C Testing: Application of a Discrete Choice Experiment with Methadone Users in Tayside, Scotland	18
JOHNDILLON	Can Dried Blood Spot Testing for Hepatitis C in Community Pharmacy Increase Uptake? Interim Reporting of a Quasi-Experimental Study	19
JOHN DILLON	How do Methadone Users Experience Community Pharmacy? A Qualitative Study to Explore the Important Attributes When Designing a Hepatitis C Virus Testing and Treatment Pathway	20
SERGII FILIPPOVYCH	Improving Quality and Scaling Up Access to HCV Treatment for the Most-At-Risk Populations within Resource Limited Settings of Ukraine	21
EMMANUEL FORTIER	The Effect of Social Functioning and Living Arrangement on Treatment Intent, Specialist Assessment and Treatment Uptake for Hepatitis C Virus Infection among People with a History of Injecting Drug Use: The ETHOS Study	22
VINCENZO FRAGOMELI	Hepatitis B and C Care in the Opiate Substitution Setting - An Integrated Nursing Model of Care	23

PRESENTER	TITLE OF PRESENTATION	#
JASON GREBELY	High Connectivity is Associated with HIV Co-Infection in the Transmission Network of People with Recent Hepatitis C Virus Infection in Australia	24
SARA GRUMMETT	Expanding Access to Hepatitis Care among People Who Inject Drugs (PWID): One Year of Fibroscans at the Kirketon Road Centre	25
BEHZAD HAJARI	Estimating the Burden of Hepatitis C Virus Infection in Iran: How the Enhanced Antiviral Treatments can Prevent the Rising Burden	26
SYUNE HAKOBYAN	HCV Re-Infection in High-Risk People who Inject Drugs	27
SYUNE HAKOBYAN	HCV HIV Co-Infected PWID Treated for HCV at Inner City Clinic	28
PETER HIGGS	Opportunistic Versus Standard Hepatitis B Vaccination for People who Inject Drugs (PWID) in the Supermix Cohort	29
ANNE LINDEBO HOLM ØVREHUS	Retention in Care and Testing Uptake are Major Obstacles to DAA Treatment among PWID Even in Integrated Services	30
BEHNAM HONARVAR	Blood-Borne Hepatitis in Opiate Users in Iran: A Poor Outlook and Urgent need to Change Nationwide Screening Policy	31
VIVIAN HOPE	Injecting and Drug Use Factors associated with Recent Hepatitis C Infection: New Findings from a National Sample of People Who Injecting Drugs in The United Kingdom (UK)	32
	Withdrawn	33
	Withdrawn	34
LISE LAFFERTY	Identifying the Social Capital of Men in Prison Screening Positive for HCV	35
MICHAEL LEVY	Incident Hepatitis C Cases Detected through a Custodial HCV Treatment Program	36
GISELA MACPHAIL	The Challenge to Engage the Whole Patient in the Era of Directly Acting Antiviral (DAA) Therapy for Hepatitis C Virus (HCV) Infections	37
GISELA MACPHAIL	"Fibroscan Days" as a Tool to Patient Engagement in the Cascade of Care for Hepatitis C (HCV)	38
LISA MAHER	Pregnancy and Contraceptive Use among Young Women Who Inject Drugs in a Hepatitis C Virus Vaccine Preparedness Study	39
NATASHA MARTIN	HCV Treatment as Prevention for PWID: Is Reinfection Rate a Useful Outcome for Decision-Makers?	40
NATASHA MARTIN	HCV Transmission among HIV-Positive Men Who have Sex with Men in The UK: Recent Epidemiology and Modelling The Impact of Scaled-Up HCV Antiviral Treatment with New DAAS for Prevention	41
MARIANNE MARTINELLO	High Adherence to Short Duration Response-Guided Treatment among People with Recent HCV Infection: The ATACH II and DARE-C I Studies	42
MOJCA MATIÐIÐ	A National Multidisciplinary Healthcare Network for Treatment of Hepatitis C in People who Inject Drugs in Slovenia	43
MOJCA MATIÐIÐ	Strategies to Manage the HCV Disease Burden in Slovenia	44
TONY MCNAUGHTON	CHANGEing the Pharmacotherapy Experience for People who Use Illicit Drugs	45
ROZALYN MILNE	From Principles to Practice: Description of a Novel Equity-Based HCV Primary Care Treatment Model for PWID	46
ALBERTO MORIGGIA	Response to DAA-Based Hepatitis C Treatment on PWUD in Substitution Therapy: First Real-Life Data from Southern Switzerland	47
MEGHAN MORRIS	Historical and Geographical Trends in Incidence of Hepatitis C Virus (HCV) Infection among People who Inject Drugs: The Inc3 Study	48

POSTER LISTING

PRESENTER	TITLE OF PRESENTATION	#
DUNG NGUYEN	Challenges on HCV Management in HCV/HIV Co-Infection Patients - Evidence from Cross-Sectional Study at NHTD (National Hospital of Tropical Diseases Hanoi - Vietnam)	49
	Withdrawn	50
GEERT ROBAEYS	Telaprevir in Combination with Peginterferon and Ribavirin in Former Injection Drug Users with Chronic Hepatitis C: Findings of the Observational Integrate Study	51
ELIZABETH PEACH	Comparison of Self-Reported Blood-Borne Virus Status with Recent Serology Results in a Local High Risk Population of People who Inject Drugs	52
ELIZABETH PEACH	Access to Blood-Borne Virus Testing and Treatment in a Local High Risk Population of People who Inject Drugs	53
ELIZABETH PEACH	Hazardous Alcohol Use and Concomitant Blood-Borne Virus Infection in a Local Urban Population of People who Inject Drugs: Implications for Approaches to Harm Reduction	54
DAVID PIEPER	Engaging Substance Users in Advocacy Campaigning	55
LEONA QUEWEZANCE	Hepatitis C : Is There Hope	56
HOMIE RAZAVI	Modelling the Impact Of Hepatitis C Virus (HCV) Treatment As Prevention Among People Who Inject Drugs (PWIDs) In Australia	57
ANDRE JEAN REMY	Treatment of the Hepatitis C in Prison in France in 2011-2012: More Patients Treated in Fewer Medical Jailhouse Units : Results of National Practice Survey	58
ANDRE JEAN REMY	Tools of Screening Viral Hepatitis B or C in Real Life: New French Model of Care	59
RACHEL SACKS-DAVIS	Associations between Neighbourhood Disadvantage and Prescription Opiate Injection in Montreal, Canada	60
DANIELA VAN SANTEN	HIV and Hepatitis C Treatment Uptake among People Who Use Drugs from the Amsterdam Cohort Studies, 1985-2013	61
JANE SCARBOROUGH	Care Provided for Hepatitis C: Congruence Between Patient Self-Identity and Stereotypes Applied by General Practitioners	62
NICK SCOTT	Cost-Effectiveness of Treating Chronic Hepatitis C Virus with Direct-Acting Antivirals in People who Inject Drugs in Australia	63
NIKRANT SHRESTHA	Integrating a Hepatitis C Peer Support Worker in a Public Drug Treatment Clinic	64
BRIAN STEPHENS	Dry Blood Spot (DBS) Testing in Injecting Drug Users	65
JACK STONE	The Potential Impact of a Hepatitis C Vaccine for People who Inject Drugs: Is a Vaccine needed in the Age of Direct-Acting Antivirals?	66
JAN TAIT	Managed Care Networks Increase HCV Testing and Referral within Community Drug Services	67
KJERSTI ULSTEIN	Feasibility and Efficacy of Sofosbuvir-Based Regimens for Treatment of HCV-Infection in a Low Threshold Setting	68
SALLY WATKINSON	Integrated Hepatitis C Services in Drug and Alcohol Settings Enable Engagement and Access to Care - A Cascade of Care	69
IOANNIS XYNOTROULAS	Treatment of Intravenous Drug Users (Idus) with Chronic Hepatitis C, Receiving Opioid Replacement with Buprenorphine in Central Greece. Effectiveness, Tolerability and Compliance	70